Takeda Pharmaceutical Company Limited (NYSE:TAK)’s ADCETRIS® (brentuximab vedotin) in combination with ECADD was authorized ...

The European Commission (EC) has approved Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) plus the ...

The drug has been approved in combination with the chemotherapy regimen etoposide, cyclophosphamide, doxorubicin, dacarbazine ...

(RTTNews) - Takeda (TAK), Tuesday announced that the European Commission has approved ADCETRIS combined with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone for newly ...

Takeda (NYSE:TAK) (4502.T) said on Monday that the European Commission approved Pfizer (NYSE:PFE) and the company's ...

Pfizer’s cancer drug Adcetris extended survival in patients with a common form of lymphoma in a late-stage trial, the company announced Tuesday, supporting Pfizer’s efforts to expand into ...

Adcetris (brentuximab vedotin) is prescribed for certain types of lymphoma. It comes as a powder that’s made into a solution for infusion into a vein. You usually receive it once every 2 or 3 weeks.

March 12 (Reuters) - Pfizer said on Tuesday its drug, Adcetris, extended survival in patients with the most common type of lymphoma in a late-stage study, bolstering efforts to expand the use of ...

Approval Based on Positive Results from the Phase 3 HD21 Trial for Stage IIb with Risk Factors/III/IV Hodgkin Lymphoma ADCETRIS-based Combination Demonstrated Superior Safety Profile and Efficacy ...

Adcetris (brentuximab vedotin) is a brand-name drug that’s prescribed for certain lymphomas in adults and some children. It’s typically given via intravenous infusion every 2 or 3 weeks by a ...